IRWDIronwood Pharmaceuticals, Inc.

$3.86+154% 1Y

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +26% year on year and operating margin widening (+42.3 points), but earnings down −1383% year on year.

2 good, 1 to watch
Revenue trend+26% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: −1% a year.

Earnings trend−1383% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction+42.3 points operating

Trailing-twelve-month operating margin, 53.6% now against 11.3% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is IRWD growing?

Ironwood Pharmaceuticals, Inc. has grown revenue −3.0% a year over three years and −1.2% a year over five, with earnings per share compounding at −46%.

−3.0%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate
−1.2%

Revenue growth, 5-year rate · −3.0% over three · growth has slowed since the five-year average

Earnings per share, 3-year rate
−46%

Earnings per share, 3-year rate · revenue −3.0% · earnings lagged revenue: the growth is costing something

Years of annual history on file
17

Years of annual history on file · FY2009 to FY2025, as filed

Details›
Revenue FY2021
$414M
Revenue FY2022
$411M
Revenue FY2023
$443M
Revenue FY2024
$351M
Revenue FY2025
$296M

Annual income statements as filed with the SEC.